MBX Biosciences, Inc. (NYSE:MBX - Get Free Report) Director Carl L. Gordon purchased 143,170 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was purchased at an average cost of $10.84 per share, with a total value of $1,551,962.80. Following the acquisition, the director now owns 3,255,000 shares in the company, valued at approximately $35,284,200. This represents a 4.60 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
MBX Biosciences Trading Down 7.1 %
NYSE MBX traded down $0.84 during trading on Friday, reaching $11.00. 86,797 shares of the company traded hands, compared to its average volume of 308,918. MBX Biosciences, Inc. has a 1-year low of $8.63 and a 1-year high of $27.50. The stock has a 50 day moving average price of $14.05.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of MBX. BNP Paribas Financial Markets acquired a new stake in MBX Biosciences during the 4th quarter valued at $27,000. Virtus ETF Advisers LLC acquired a new stake in shares of MBX Biosciences in the fourth quarter valued at $64,000. Deutsche Bank AG bought a new position in shares of MBX Biosciences in the fourth quarter valued at about $80,000. Corebridge Financial Inc. acquired a new position in MBX Biosciences during the 4th quarter worth about $103,000. Finally, Wells Fargo & Company MN acquired a new position in MBX Biosciences during the 4th quarter worth about $108,000.
About MBX Biosciences
(
Get Free Report)
MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.
Further Reading
Before you consider MBX Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MBX Biosciences wasn't on the list.
While MBX Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
